INMB (inmunebio.com) יחס שווי שוק לשווי בספרים

INmune Bio, Inc. (INMB) specializes in developing TNF inhibitors, utilizing the unique XPro drug to combat neuronal degeneration in Alzheimer's disease. The financial model relies on government support and the therapy of inflammatory pathologies, with the indicator standing at 1.86. The company's price action available on the GURU.Markets chart is supported by the readiness of modern laboratories and contract manufacturing sites for mass drug production.

Evaluating the stability of INmune Bio, Inc. (INMB), I analyze the market-to-book ratio. This coefficient compares current quotes with the actual value of net assets, filtering out market volatility. By studying the price-to-book value trend, an investor can determine the degree of business overvaluation. For INmune Bio, Inc. (INMB), this indicator is critical due to high R&D expenditures. The risks of failed trials make book value the primary benchmark for safety.